The Uromigos Episode 59: Ipatercertib in Biomarker Positive Castrate Resistant Prostate Cancer

By The Uromigos - Last Updated: September 20, 2020

Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered castrate resistant prostate cancer. A positive R3 trial in the ESMO plenary session.

Post Tags:Uromigos-ESMOUromigos-Prostate Cancer
Advertisement

Related Podcasts

Episode 370: Artificial Intelligence in Medical Oncology
Episode 369: Paper of the Month With Bishoy Faltas
Uromigos-Bladder Cancer
Episode 368: Radiomics in RCC - Live From IKCS
Uromigos-Kidney Cancer
Episode 367: Abiraterone vs AR Inhibitors (Fanta vs Coke) in Prostate Cancer
Uromigos-Prostate Cancer
Episode 366: ARPIs in Prostate Cancer - Are They Different?
Uromigos-Prostate Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy